All Releases
 |
Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
Nov 6, 2008
|
15.6 KB |
| |
EMERYVILLE, Calif., Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced its financial results for the quarter ended September 30, 2008, the first quarter of the company's fiscal year ending June 30, 2009. Revenue for the three months ended September 30, 2008 was $...
|
|
Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
Nov 5, 2008
|
10.7 KB |
| |
EMERYVILLE, Calif., Nov 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII), today announced that Paul E. Freiman, President and Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference November 10 to 12 at the New York Palace Hotel.
Mr. Freiman's pr...
|
|
Neurobiological Technologies Sets Date for First Quarter Financial Results
Nov 4, 2008
|
11.3 KB |
| |
EMERYVILLE, Calif., Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its first quarter 2009 financial results, for the quarter ended September 30, 2008, and host a conference call on November 6, 2008.
Hosting the call will be Paul E. Freima...
|
|
Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
Nov 3, 2008
|
10.5 KB |
| |
EMERYVILLE, Calif., Nov 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $2.0 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's dise...
|
|
Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
Oct 27, 2008
|
10.7 KB |
| |
EMERYVILLE, Calif., Oct 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII), today announced that Paul E. Freiman, President and Chief Executive Officer, will present at the Seventh Annual BIO Investor Forum on October 29 and 30, 2008 at The Palace Hotel in San Francisco. Mr. Freiman's presen...
|
|
Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
Oct 13, 2008
|
13.8 KB |
| |
EMERYVILLE, Calif., Oct 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that following a meeting with the U.S. Food and Drug Administration to discuss the Viprinex(TM) (ancrod) Phase 3 clinical program for acute ischemic stroke, the company plans to consolidate an...
|
|
Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
Oct 10, 2008
|
10.8 KB |
| |
EMERYVILLE, Calif., Oct 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will hold a conference call on Monday, October 13, to provide an update on the Viprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke. Hosting the call will be Paul E. Freim...
|
|
Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
Sep 25, 2008
|
13.6 KB |
| |
EMERYVILLE, Calif., Sept 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that previously found excess symptomatic intracranial hemorrhage in an earlier European trial of ancrod (now Viprinex(TM)) for the treatment of acute ischemic stroke may be minimized with avo...
|
|
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2008
Sep 16, 2008
|
15.3 KB |
| |
EMERYVILLE, Calif., Sept 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced its financial results for its fiscal fourth quarter and year ended June 30, 2008.
For fiscal year 2008, the Company reported revenue of $14.8 million, compared to revenue of $17.7 million...
|
|
Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Sep 11, 2008
|
11.7 KB |
| |
EMERYVILLE, Calif., Sept 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its fiscal 2008 fourth quarter and year-end financial results on September 16, 2008.
The Company will also host a call to discuss its financial results. Details for the f...
|
|
Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
Aug 12, 2008
|
12.8 KB |
| |
EMERYVILLE, Calif., Aug 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that enrollment into its two Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for the treatment of acute ischemic stroke has reached the level of patients necessary to conduct a planne...
|
|
Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
Aug 4, 2008
|
10.5 KB |
| |
EMERYVILLE, Calif., Aug 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $2.1 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's dise...
|
|
Neurobiological Technologies' CEO to Retire on December 31, 2008
Jul 7, 2008
|
11.1 KB |
| |
EMERYVILLE, Calif., July 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that Paul E. Freiman, president and chief executive officer (CEO), has announced his intent to retire on December 31, 2008. The Company expects Mr. Freiman to continue to serve on the Board. ...
|
|
Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
May 14, 2008
|
13.7 KB |
| |
NICE, France, May 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) reported for the first time at the European Stroke Conference detailed analyses supporting the dosing regimen in NTI's two ongoing Phase 3 studies of Viprinex(TM) (ancrod) for ischemic stroke. The company also prov...
|
|
Neurobiological Technologies Reports Third Quarter Financial Results
May 12, 2008
|
16.0 KB |
| |
EMERYVILLE, Calif., May 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced financial results for its fiscal third quarter and the nine months ended March 31, 2008.
Revenues for the three months ended March 31, 2008 were $3.7 million compared to $4.9 million for t...
|
|
Neurobiological Technologies Sets Date for Third Quarter Financial Results
May 8, 2008
|
11.3 KB |
| |
EMERYVILLE, Calif., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its third quarter 2008 financial results, for the quarter ended March 31, 2008, on May 12, 2008 and host a conference call on May 13, 2008.
Hosting the call will be Paul E....
|
|
Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
Apr 30, 2008
|
10.5 KB |
| |
EMERYVILLE, Calif., April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received approximately $2.0 million from Merz Pharmaceuticals GmbH (Merz) for sales by Merz and its marketing partners of Memantine for the treatment of moderate-to-severe Alzheimer'...
|
|
Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
Apr 16, 2008
|
11.3 KB |
| |
EMERYVILLE, Calif., April 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that after a scheduled review, an independent data safety monitoring board (DSMB) has recommended continuation of the company's two Phase 3 clinical trials to determine whether a brief intr...
|
|
Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
Apr 1, 2008
|
12.0 KB |
| |
EMERYVILLE, Calif., April 1, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that, effective April 1, 2008, Matthew M. Loar has been appointed Chief Financial Officer. Mr. Loar will be based at the Company's headquarters in Emeryville. Mr. Loar joins the compan...
|
|
Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease
Mar 3, 2008
|
13.8 KB |
| |
EMERYVILLE and NOVATO, Calif., March 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) and the Buck Institute for Age Research (Buck) announced today they have entered into a collaboration and exclusive license agreement to develop a novel therapy for Alzheimer's Disease (AD). Under the term...
|
|
|
